MedTrace Logo

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

NCT03624543 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-01-30

No results posted yet for this study

Summary

The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer. Patients will have already had at least one chemotherapy treatment for their disease at this stage.

Conditions

Interventions

DRUG

CFI-400945

32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily

Sponsors & Collaborators

  • Stand Up To Cancer Canada-Canadian Cancer Society Breast Cancer Dream Team

    collaborator UNKNOWN

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • David Cescon · Princess Margaret Cancer Centre, Toronto, ON

  • Rossanna Pezo · Sunnybrook Health Sciences Centre, Toronto, ON

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-14
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03624543 on ClinicalTrials.gov